Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Burkitt Lymphoma 14Leukemia, Biphenotypic, Acute 9Leukemia, Myeloid, Acute 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Myelodysplastic Syndromes 3Lymphoma 3Breast Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Primary Myelofibrosis 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Polycythemia Vera 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Mouth Neoplasms 1Meningeal Neoplasms 1

Interventions

Carboplatin 4pertuzumab 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Paclitaxel 2Oxaliplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1talazoparib 1sarilumab 1relugolix 1regorafenib 1pexidartinib 1pembrolizumab 1patritumab 1olaparib 1niraparib 1nimotuzumab 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pathologic Complete Response × Methotrexate × Clear all
NCT04314219 2025-03-13

PTCy-PMAT

King Faisal Specialist Hospital & Research Center

Phase 3 Recruiting
264 enrolled
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡